Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal BCMA-CD19 CAR-T (BRL-302) in Refractory NMOSD
NCT06633042Phase 1Not yet recruiting
- Sponsor
- BRL Medicine Inc.
- Start
- Nov 2024
- Primary completion
- Oct 2025
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of Universal BCMA-CD19 CAR-T in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by BRL Medicine Inc. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 12 months. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
Universal BCMA-CD19 CAR-T
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT06633042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06633042.